Xtant Medical Holdings Inc (XTNT)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.38-5.21%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Positive operating cash flow: OCF -$2.1M vs >$0 target.
Xtant raised 2026 revenue guidance to $101M-$105M. The company sold Coflex and CoFix products for $17.5M to focus operations. Management aims to maintain positive cash flow despite recent challenges.
Revenue declined sharply from $32.36M in 2025-Q4 to $20.88M in 2026-Q1. Cash flow from operations turned negative at -$2.11M in 2026-Q1. The company remains loss-making with high risk and weak earnings.
The price is about 1% above our fair value near $0.42. Analysts expect about -6% revenue decline, reflecting skepticism on turnaround progress.
Breaks if: divestiture not completed or reversed
Completed the sale of Coflex and CoFix products for $17.5 million.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is weakened due to recent financial performance and a shift from robust to fragile conditions.
The market appears to price in a low expectations gap, suggesting that XTNT is seen as cheap compared to its peers. However, the overall valuation reflects a premium, indicating some cautious optimism despite the recent earnings miss.
Management is focused on expanding its biologics portfolio and reducing debt, which are positive steps. However, recent financial performance has been weak, and cash reserves are declining, indicating potential liquidity concerns.
The long-term thesis hinges on XTNT's ability to reverse its recent negative trends, particularly by raising guidance in the next quarter. Additionally, broader sector performance and economic conditions will significantly impact its trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The primary driver is that the reason to own XTNT has weakened. Recent financial performance fell from the robust 73rd to the 4th percentile of its sector. However, the company increased its full-year 2026 revenue guidance, which supports growth objectives.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: operating cash flow remains negative over next 4 quarters
Breaks if: full-year 2026 revenue falls below $101 million
In the next 1 to 3 years, XTNT's performance will depend on effective management execution and external economic factors. Not investment advice.